http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015123439-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate | 2015-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9820e7b072b0086d1d407ca2e2fa403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2ccf7920681c135796e482df6ae4ae9 |
| publicationDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2015123439-A2 |
| titleOfInvention | Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma |
| abstract | Methods of promoting neuroblast differentiation in subjects with neuroblastoma by administering an. agent to a subject with neuroblastoma are provided herein. The agent may be a heparin -sulfate proteoglycan co-receptor, heparin sulfate or a heparin analog. Promotion of neuroblast differentiation, may suppress neuroblast growth and treat neuroblastoma... Methods of determining a prognosis for a subject with neuroblastoma are also provided. The methods include measuring the level of at least one marker selected from FGF2, FGFR1, ID1, TĪ²RIII, SDC3, SDC4, GPC3 and GPC1 in a sample from the subject and comparing the level in the subject to a reference level. If the levels of any of the markers are higher than the reference level the subject has a good prognosis. If the levels are lower than the reference level, the prognosis is poor. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018036490-A1 |
| priorityDate | 2014-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.